Highlights
- A Notice of Grant received from the Chinese Patent Office for IMU’s oncolytic virotherapy CF33.
- Previously, grants were obtained in South Korea and Japan.
- The patents extend protection for the method of composition and method of use until 2037.
- China is the largest pharmaceutical market in the Asian region.
Shares of Imugene Limited (ASX: IMU) jumped by over 7% during the early morning trading session on 4 April 2024, following an exciting company update regarding its oncolytic virotherapy CF33.
The company has secured a patent in China for its oncolytic virotherapy CF33. This adds to previous grants obtained in Japan and South Korea, underscoring the global recognition of Imugene's innovative oncolytic virotherapy, CF33.
The grant protects CF33 which covers VAXINIA (CF33-hNIS) and CHECKvacc (CF33-hNIS-antiPDL1).
Details of the patent granted in China:
The title of the patent is –
The patent extends protection to the method of use and composition of IMU’s licensed oncolytic virotherapy to 2037.
At the helm of this groundbreaking technology is Professor Yuman Fong, whose expertise in oncolytic viruses has been pivotal.
CF33, a chimeric vaccinia poxvirus developed in his laboratory, is designed to selectively target and eliminate tumor cells while stimulating the body's immune response against cancer.
IMU shares traded at AU$0.112 apiece at the time of writing on 4 April 2024.